Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS

2018 ◽  
Vol 28 (4) ◽  
pp. 399-405 ◽  
Author(s):  
Robert Zivadinov ◽  
Jennie Medin ◽  
Nasreen Khan ◽  
Jonathan R. Korn ◽  
Niels Bergsland ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Volume ◽  
Mri Brain

Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics

2016 ◽  
Vol 26 (5) ◽  
pp. 532-538 ◽  
Author(s):  
Angela Vidal-Jordana ◽  
Jaume Sastre-Garriga ◽  
Francisco Pérez-Miralles ◽  
Deborah Pareto ◽  
Jordi Rio ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Brain Volume ◽  
First Year ◽  
Volume Loss ◽  
Brain Volume Loss ◽  
Regional Brain ◽  
Regional Brain Volume

scholarly journals Learning ability correlates with brain atrophy and disability progression in RRMS

2018 ◽  
Vol 90 (1) ◽  
pp. 38-43 ◽  
Author(s):  
Maria Pia Sormani ◽  
Nicola De Stefano ◽  
Gavin Giovannoni ◽  
Dawn Langdon ◽  
Daniela Piani-Meier ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Volume ◽  
Practice Effect ◽  
Wilcoxon Test ◽  
Learning Ability ◽  
Lesion Volume ◽  
Volume Loss ◽  
Disability Progression ◽  
Brain Volume Loss ◽  
Quartile Group

ObjectiveTo assess the prognostic value of practice effect on Paced Auditory Serial Addition Test (PASAT) in multiple sclerosis.MethodsWe compared screening (day −14) and baseline (day 0) PASAT scores of 1009 patients from the FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis (FREEDOMS) trial. We grouped patients into high and low learners if their PASAT score change was above or below the median change in their screening PASAT quartile group. We used Wilcoxon test to compare baseline disease characteristics between high and low learners, and multiple regression models to assess the respective impact of learning ability, baseline normalised brain volume and treatment on brain volume loss and 6-month confirmed disability progression over 2 years.ResultsThe mean PASAT score at screening was 45.38, increasing on average by 3.18 from day −14 to day 0. High learners were younger (p=0.003), had lower Expanded Disability Status Scale score (p=0.031), higher brain volume (p<0.001) and lower T2 lesion volume (p=0.009) at baseline. Learning status was not significantly associated with disability progression (HR=0.953, p=0.779), when adjusting for baseline normalised brain volume, screening PASAT score and treatment arm. However, the effect of fingolimod on disability progression was more pronounced in high learners (HR=0.396, p<0.001) than in low learners (HR=0.798, p=0.351; p for interaction=0.05). Brain volume loss at month 24 tended to be higher in low learners (0.17%, p=0.058), after adjusting for the same covariates.ConclusionsShort-term practice effects on PASAT are related to brain volume, disease severity and age and have clinically meaningful prognostic implications. High learners benefited more from fingolimod treatment.

Obesity and brain volume loss in multiple sclerosis

Neurology ◽  
2018 ◽  
Vol 91 (24) ◽  
pp. 1079-1080
Author(s):  
Ruth Ann Marrie ◽  
Helmut Butzkueven ◽  
Alberto Ascherio
Keyword(s):  
Multiple Sclerosis ◽  
Brain Volume ◽  
Volume Loss ◽  
Brain Volume Loss

An Automatic MRI Brain Volume Alignment Tool

2010 ◽  
Author(s):  
Deborah Sturm ◽  
Philip Koshy ◽  
Diana Kovalerchik ◽  
Nirav Thakkar
Keyword(s):  
Brain Volume ◽  
Mri Brain ◽  
Alignment Tool
Sign in / Sign up

Export Citation Format

Share Document